Well I have a TGT of £41, sounds as rampy as Porky’s messages but not meant to be. If profit is £432 million for the year a PE ratio of 6.25 is £2.7billion = £41.
Will I be correct, who knows but I like to think there is a massive upside in 2021 for this share and it will be another very interesting year.
Ventura, that’s not true regarding the intensity. I know people who work in track and trace, they have spoken to a couple who both had COVID earlier in 2020 (positive tests), one of them close to hospitalisation, the other mild symptoms. When they had it the second time round, the symptoms flipped, the one who was ok the first time was nearly hospitalised the second time and vice versa.
As I’ve said before I know people who work in test and trace. It seems this new (UK) variant has slightly different symptoms to the previous one, the SA one May differ and same with the Brazilian one.
The government are one step behind the pandemic at every point. People are yet again having to lie about symptoms to get a test, I know of this happening in lots of locations where they have symptoms of a cold.
Either mass testing or as porky said, tests that can pick up different variants to assess symptoms to prevent people spreading is key.
And here come the trolls. Funds were selling HZM at 3p and it’s now around 10p. They’re not privy to inside information as that would be insider trading and they would be investigated by the FCA. If they were worried about the results they’d sell the entire 2million shares.
Realistically you don’t know at what price they started buying. They could have started after the vaccine news at £6 and continued all the way up.
Results will be excellent, I have no doubt.
Mapper, I read an article yesterday by a leading scientist in Australia. Australia has deemed the efficiency of the Single jab AZN vaccine not enough to provide herd immunity.
Furthermore until the whole world has been vaccinated tests will be required pre flight. As a minimum I can see this continuing well into 2022, especially when you look at vaccine timelines. I can however see prices dropping somewhat as >£100 is pretty extortionate.
Porky, I seriously don’t get it and it does drive me insane. The frustrating thing is no matter what the management do it’s up to the market to value it.
On a plus side all of the brokers will do new notes within a week or so of the trading update, fingers crossed with new highs. Hopefully that will give people the insight they need (alongside an incredible trading update) to pay higher prices.
Some PIs seem naive thinking NCYT is expensive because it’s £8, I don’t think Twatter helps. They don’t understand the small number of shares in issue.
The only other possibility is that the dual listing with the french market is doing us no favours, they seem to drive the daily fluctuations as they own 70%..... time for a delisting?
Soder, fair analogy, however when people get infected a second time it infects them differently.
I know someone who works for test and trace, they told me about a couple who had COVID back in March. The husband was on the verge of being hospitalised and the wife had mild symptoms. They both had COVID again in June and the husband had mild symptoms and the wife was on the verge of being hospitalised.
It’s not a one size fits all sadly.
Not sure if this has been posted, can’t find it on the thread and have had a few days off here.
The government has just signed a contract for 2mil LFT from surescreen for key workers that can’t work from home. Interestingly they are antibody tests.
https://www.surescreen.com/products/covid-19-coronavirus-rapid-test-cassette
The test: The test is a lateral flow immunoassay test and operates in a similar way to a pregnancy test. Embedded into the test strip are antibodies that bind to a COVID-19 specific biomarker, Immunoglobulin G (IgG), and another infection biomarker, Immunoglobulin M (IgM). When a sample (blood, serum or plasma) is added to one end of the test, it flows along the test strip and interacts with these antibodies. If the patient has contracted COVID-19, the biomarkers in their blood will bind to the antibodies on the test strip, leaving a visible test line. If the patient doesn’t have COVID-19, no biomarkers should be present in their blood and no test line will be visible. There are separate test lines for IgG and IgM and only one needs to be visible for a positive result.
Sensitivity: 96.55%
Specificity: 99.67%
Over 98% accurate
The microgen test: The Microgen Bioproducts® SARS-CoV-2 IgG EIA is a high-performance ELISA test for the qualitative detection of IgG antibodies. The test is intended for screening patients suspected of being infected with the SARS-CoV-2 virus.
Provided in a convenient 480 reaction format (5×96 well plates) including all additional reagents to perform the assay. This test is functional with human serum and plasma samples.
Accurate detection of SARS-CoV-2 IgG antibodies
High Sensitivity and Specificity
<1 hour 30 minutes incubation time
Functional with human plasma and serum samples
No cross-reactivity with common viral pathogens
Validated for manual application, however also suitable for high-throughput ELISA automation
No additional re-agents required
Product Information
Specificity: 99.4%
Sensitivity: 100%
I wonder whether this could open up a new market to use microgen’s tests in a similar way to the innova LFT and surescreen, instead of solely post vaccination antibody checks.
Thoughts....
Mikey, afraid it doesn’t work like that. Yes the number or shares x the share price gives you the market cap (the valuation of the company). However if the company was to reduce the shares in issue, the only thing that would change is the liquidity.
Finally that number of warrants is peanuts in the grand scheme of things and will not impact the price.
There are lots of companies with a lot more shares in issue than this one.
Listing is in:
https://backend.otcmarkets.com/otcapi/company/financial-report/268005/content
https://twitter.com/tymerzofficial/status/1347310833177677824?s=21
https://uk.sports.yahoo.com/news/argo-blockchain-hargreaves-lansdown-investors-121343406.html